Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma

Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Study ID
NCT07168291
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Burkitt Lymphoma
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Follicular Lymphoma ( FL)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion — DRUG
    Cyclophosphamide 250 mg/m2 and fludarabine 30 mg/m2 IV infusion on day -5, -4, and -3. AbTCR (anti-CD19/CD22)-T cell IV infusion on day 0.

Study Details

This is an open-lable, single arm, non-randomized study to evaluate the primary safety and efficacy of the novel bispecific AbTCR (anti-CD19/CD22)-T cells in patients with relapsed or refractory B-cell lymphoma

Key Dates

First listed
Sep 11, 2025
Start date
Dec 31, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
3 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Conditioning chemotherapy plus AbTCR (anti-CD19/CD22)-T cells
    The trial will enroll 3 patients with relapsed or refractory B-cell lymphoma.

Primary Outcome Measure

Incidence of Treatment-related Adverse Events [ Time Frame: 3 years ]

Central Contacts

Related Studies